P-069 Idecabtagene Vicleucel (ide-cel) in Patients (pts) with Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): the 5-year Follow-Up Analysis from KarMMa | Publicación